Nobel Laureate Ada Yonath, Pioneer in Ribosome Research, Dies at 87

Professor Ada Yonath, a Nobel Prize laureate in Chemistry and a distinguished scientist at the Weizmann Institute of Science, has passed away at the age of 87. Yonath was renowned for being the first to elucidate the structure and function of the ribosome, the cellular machinery responsible for protein synthesis. Her groundbreaking work opened significant avenues in drug development, with further potential yet to be realized.

Born in Jerusalem in 1933 to Polish immigrants, Yonath displayed an early curiosity for science, conducting experiments at home despite financial hardship and minor injuries. She pursued chemistry and biophysics at the Hebrew University of Jerusalem before earning her doctorate at the Weizmann Institute. Following postdoctoral research at Carnegie Mellon and MIT, she returned to the Weizmann Institute to establish her own lab, where she worked until her death. She also held senior positions at the Max Planck Institute and lectured at the University of Chicago.

Yonath's Nobel Prize in 2009 recognized her pivotal research on the ribosome, which translates the body's genetic code into proteins. Despite her achievements, she recounted facing initial challenges, including a small office near the restrooms at the Weizmann Institute. However, she remained dedicated to the institute, citing its support for her research even when colleagues abroad doubted her theories.

She was known for her accessibility, engaging with students and diverse audiences, and assisting fellow scientists. Yonath viewed her Nobel Prize not just as an honor but also as an opportunity to connect with more students, though she noted it did not bring additional funding, with some assuming she no longer needed it.

The primary application of her ribosome research led to the development of new types of antibiotics, targeting bacterial ribosomes to combat resistance. While no antibiotic has yet been developed directly from this approach, her findings on ribosomal differences are crucial for future targeted drug development. Her methods for understanding ribosome structure are foundational to several new antibiotics currently in development. In recent years, Yonath also investigated genetic diseases linked to human ribosome variations, including anemias, and participated in research mapping the ribosome of the Leishmania parasite, potentially leading to treatments for the disease.